-
Start Preamble
Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee.
The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.
Name of Committee: National Cancer Institute Clinical Trials and Translational Research Advisory Committee; Ad hoc Clinical Trials and Strategic Planning Subcommittee.
Date: February 25, 2013.
Time: 5:00 p.m. to 6:00 p.m.
Agenda: Update on the NCI National Clinical Trials Network (NCTN) Working Group of the Ad hoc Clinical Trials Strategic Planning Subcommittee. Dial in number: 1-866-652-9542 and Passcode: 4596704.
Place: National Institutes of Health, 6120 Executive Blvd., Suite 300, Rockville, MD 20852, (Telephone Conference Call).
Contact Person: Sheila A. Prindiville, MD, MPH, Director, Coordinating Center for Clinical Trials, Office of the Director, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd., 3rd Floor Suite, Bethesda, MD 20892, 301-451-5048, prindivs@mail.nih.gov.
Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.
Information is also available on the Institute's/Center's home page: http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm,, where an agenda and any additional information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)
Start SignatureDated: January 17, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-01330 Filed 1-23-13; 8:45 am]
BILLING CODE 4140-01-P
Document Information
- Comments Received:
- 0 Comments
- Effective Date:
- 2/25/2013
- Published:
- 01/24/2013
- Department:
- National Institutes of Health
- Entry Type:
- Notice
- Document Number:
- 2013-01330
- Dates:
- February 25, 2013.
- Pages:
- 5190-5190 (1 pages)
- PDF File:
- 2013-01330.pdf
- Supporting Documents:
- » License Agreements; Start-Up Exclusive Evaluation Option: Activators of Human Pyruvate Kinase to Treat Cancer
- » Meetings: Eunice Kennedy Shriver National Institute of Child Health and Human Development
- » Meetings: National Institute of Nursing Research
- » Meetings: National Institute of Allergy and Infectious Diseases
- » Meetings: National Eye Institute
- » Meetings: Eunice Kennedy Shriver National Institute of Child Health and Human Development
- » Meetings: Center for Scientific Review
- » Meetings: Center for Scientific Review
- » Meetings: National Institute of Environmental Health Sciences
- » Meetings: National Human Genome Research Institute